Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netupitant - Helsinn

Next Previous
Drug Profile

Netupitant - Helsinn

Alternative Names: R 1124; Ro 67-3189/000

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Helsinn; Taiho Pharmaceutical
  • Class Antiemetics; Antineoplastics; Pyridines; Small molecules
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chemotherapy-induced nausea and vomiting
  • Preclinical Cancer
  • Discontinued Overactive bladder; Pruritus

Most Recent Events

  • 28 May 2025 Preclinical trials in Cancer in Switzerland (unspecified route) prior to May 2025
  • 28 May 2025 Pharmacokinetics and pharmacodynamics data from a preclinical studies in Cancer presented at the 126th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2025)
  • 26 Apr 2022 No development reported - Phase-II for Chemotherapy-induced nausea and vomiting (Combination therapy, In adolescents, In children, In infants, In neonates, Prevention) in USA, Russia, Serbia, Ukraine (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top